Suzhou Highfine Biotech Co Ltd (301393)

Currency in CNY
56.36
-1.20(-2.09%)
Delayed Data·

301393 Financial Summary

Key Ratios

P/E Ratio37.1
Price/Book2.2
Debt / Equity0.12%
Return on Equity6.13%
Dividend Yield0.68%
EBITDA120.99M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2023
01/01
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.30%
Dividend Yield
0.68%
Industry Median 1.40%
Annualised payout
0.39
Paid annually
5-Years Growth
-
Growth Streak

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 60.00
(+6.46% Upside)

Earnings

Latest Release
Apr 27, 2025
EPS / Forecast
0.32 / --
Revenue / Forecast
135.21M / --
EPS Revisions
Last 90 days

FAQ

What were Suzhou Highfine Biotech's earnings for the latest quarter?

The Suzhou Highfine Biotech EPS (TTM) is 1.30. Suzhou Highfine Biotech reported sales of 135.21, net income of 34.80, and EPS of 0.32 for the latest quarter.

What was Suzhou Highfine Biotech's net income for the latest quarter?

Suzhou Highfine Biotech's net income for the latest quarter was 34.80.

How did Suzhou Highfine Biotech's performance compare year-over-year in the latest quarter?

The company's revenue moved from 123.72 in the previous quarter to 135.21 in the latest quarter, and net income moved from 37.72 to 34.80 compared to the previous quarter.

What is Suzhou Highfine Biotech's net profit margin on a TTM basis?

Suzhou Highfine Biotech's trailing twelve months (TTM) net profit margin is 29.67%.

How does Suzhou Highfine Biotech's debt to equity ratio compare to industry standards?

Suzhou Highfine Biotech's total debt-to-equity ratio is 0.12%.

What is Suzhou Highfine Biotech's return on investment on a TTM basis?

Suzhou Highfine Biotech's trailing twelve months (TTM) return on investment (ROI) is 6.13%.

Did Suzhou Highfine Biotech gain or lose cash last quarter?

In the latest quarter, Suzhou Highfine Biotech's net change in cash was 190.42 million.

What were Suzhou Highfine Biotech's total assets and liabilities in the latest quarter?

As of the latest quarter, Suzhou Highfine Biotech reported total assets of 2,386.55 million and total liabilities of 68.87 million.

How has Suzhou Highfine Biotech's total revenue grown this year?

Suzhou Highfine Biotech's total revenue was 123.72 in the previous quarter and 135.21 in the latest quarter.

What is Suzhou Highfine Biotech's gross margin on a TTM basis?

Suzhou Highfine Biotech's trailing twelve months (TTM) gross margin is 39.76%.

What was Suzhou Highfine Biotech's revenue per share for the latest quarter?

Suzhou Highfine Biotech's revenue per share for the latest quarter was 7.81.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.